 Provider News MaineFebruary 2022 Anthem Maine Provider NewsNotices of material changes/amendments to contract may apply for new or updated reimbursement policies, medical policies, or prior authorization requirements. In this issue, please reference the following article:
- Specialty pharmacy updates - February 2022
- Clinical criteria updates for specialty pharmacy
The Consolidated Appropriations Act (CAA) effective January 1, 2022, contains a provision that requires online provider directory information be reviewed and updated (if needed) at least every 90 days. We are asking you to review your online provider directory information to help ensure Anthem members can locate the most current information for in-network providers and facilities.
You can help us ensure your online provider directory information is current by:
- Reviewing your online provider directory information on a regular basis to ensure it is correct. You can check your directory listing on Anthem’s Find Care Consumers, members, brokers, and providers use the Find Care tool to identify in-network physicians and other healthcare providers supporting member health plans. To ensure we have your most current and accurate information, please take a moment to access Find Care. Go to anthem.com, select Providers, then under Provider Overview, choose Find Care.
- Submitting updates and corrections to your directory information by using our online Provider Maintenance Form. Online update options include:
- add/change an address location
- name change
- tax ID changes
- provider leaving a group or a single location
- phone/fax number changes
- closing a practice location
Once you submit the Provider Maintenance Form, you will receive an email acknowledging receipt of your request. Visit the Provider Maintenance Form landing page, then select your state, for complete instructions.
The Cancer Care Navigator (CCN) program is a comprehensive cancer support solution for oncologists and Anthem members who are at high risk for complications during treatment. This program is aimed at helping to simplify the complexities of cancer care for members.
Providers are given a single point of contact to connect the practice to the right people at Anthem to help lessen administrative burdens. CCN also gives the practice access to Anthem’s advanced predictive analytics to help identify patients at high risk for complications, in turn allowing providers the opportunity to take preventive action and guide targeted interventions.
Patients are provided with a wealth of support through supplemental services (dietitians, pharmacists, etc.), medication adherence assistance, individualized care plans, and goal setting, as well as after-hours telephonic and digital support.
CCN is the ultimate support service to improve the care experience and quality of life to allow patients time to focus on overall health and well-being. Please feel free to reach out to the CCN team at 833-649-0669.
The Consumer Assessment of Healthcare Providers and Systems (CAHPS) is an annual standardized survey conducted starting February 2022 through May2022 to assess consumers’ experience with their provider and health plan. A random sample of your adult or child patients may get the survey. Over half of the questions used for scoring are directly impacted by providers. These questions are:
- When you needed care right way, how often did you get care as soon as you needed?
- How often did you get an appointment for a check-up or routine care as soon as you needed?
- How often was it easy to get the care, tests, or treatment you needed?
- How often did you get an appointment to see a specialist as soon as you needed?
- How often did your personal doctor seem informed and up-to-date about the care you got from other doctors or other health providers?
- How would you rate your personal doctor?
- How would you rate the specialist you see most often?
- How would you rate all your health care in the last 6 months?
Interested in how you can improve CAHPS performance? We offer an online course for providers and office staff designed to learn how to improve communication skills, build patient trust and commitment, and expand your knowledge of the CAHPS survey. The Improving the Patient Experience course is available at no cost and is eligible for one CME credit by the American Academy of Family Physicians. It can be accessed at: https://www.mydiversepatients.com/le-ptexp.html
Share information with patients about taking an active role in their heart health
National Wear Red Day is a great way to keep heart aware. It is also a great opportunity to have a conversation with your patients about their heart health. The Centers for Disease Control and Prevention (CDC) has information you can share with your patients, including a helpful Know the Facts about Heart Disease flyer that’s free for health care professionals.
Controlling high blood pressure, diabetes, extra weight and unhealthy diets are heart disease contributors that you can help your patients recognize. For information about these heart disease risks to share with your patients, use the CDC website for toolkits, flyers and give-a-ways.
Measure Up: Controlling High Blood Pressure (CBP)
Known as the “silent killer,” high blood pressure or hypertension increases the risk of heart disease.
The HEDIS® measure CBP looks at the percentage of patients 18-85 years of age who had a diagnosis of hypertension and whose blood pressure was adequately controlled (140/90) in the measurement year. Record all blood pressure readings and the dates they were taken being sure to record the exact reading. Blood pressure readings captured during a telehealth, virtual care, telephone or e-visit should also be recorded.
Measure Up: Statin Therapy for Patients with Cardiovascular Disease and Diabetes (SPC/SPD)
Statins are effective at lowering cholesterol and protecting against a heart attach and stroke. Patients with diabetes also have elevated cardiovascular risk.
- Statin therapy for patients with cardiovascular disease (STC). HEDIS measure assesses males 21-75 years of age and females 40-75 years of age who have clinical atherosclerotic cardiovascular disease and who received and adhered to statin therapy.
- Statin therapy for patients with diabetes (STD) assesses adults 40-75 years of age who have diabetes and who do not have clinical ASCVD, who received and adhered to statin therapy.
Adherence to prescribed medication is key to patient care and SPC/SPD measure success.
Anthem specialty pharmacy updates are listed below.
Prior authorization clinical review of non-oncology use of specialty pharmacy drugs is managed by Anthem’s medical specialty drug review team. Review of specialty pharmacy drugs for oncology use is managed by AIM Specialty Health® (AIM), a separate company.
Please note, inclusion of National Drug Code (NDC) code on your claim will help expedite claim processing of drugs billed with a not otherwise classified (NOC) code.
Prior authorization updates
Effective for dates of service on and after May 1, 2022, the following specialty pharmacy codes from current or new clinical criteria documents will be included in our prior authorization review process.
Access our clinical criteria to view the complete information for these prior authorization updates.
Clinical Criteria
|
Drug
|
HCPCS or CPT Code(s)
|
+*ING-CC-0204
|
Tivdak
|
J3490, J3590, J9999
|
+ING-CC-0072
|
Byooviz
|
J3590
|
+ING-CC-0068
|
Skytrofa
|
J3490
|
* Oncology use is managed by AIM.
+ The applicable policy is attached to this article in PDF format.
Note: Prior authorization requests for certain medications may require additional documentation to determine medical necessity.
Step therapy updates
Effective for dates of service on and after May 1, 2022, the following specialty pharmacy codes from current or new clinical criteria documents will be included in our existing specialty pharmacy medical step therapy review process.
Access our clinical criteria to view the complete information for these prior authorization updates.
Clinical Criteria
|
Status
|
Drug
|
HCPCS or CPT Code(s)
|
+ING-CC-0072
|
Non-Preferred
|
Byooviz
|
J3590
|
+ The applicable policy is attached to this article in PDF format.
Quantity limit updates
Effective for dates of service on and after May 1, 2022, the following specialty pharmacy codes from current or new clinical criteria documents will be included in our quantity limit review process.
Access our clinical criteria to view the complete information for these prior authorization updates.
Clinical Criteria
|
Drug
|
HCPCS or CPT Code(s)
|
+ING-CC-0072
|
Byooviz
|
J3590
|
+ The applicable policy is attached to this article in PDF format.
The following clinical criteria documents were endorsed at the November 19, 2021 Clinical Criteria meeting. Visit our website to access the clinical criteria information.
New clinical criteria effective December 1, 2021
The following clinical criteria is new.
- ING-CC-0204 Tivdak (tisotumab vedotin-tftv)
Revised clinical criteria effective December 1, 2021
The following clinical criteria was reviewed with no significant change to the medical necessity indications or criteria.
- ING-CC-0167 Rituximab Agents for Oncologic Indications
Revised clinical criteria effective December 1, 2021
The following clinical criteria were revised to expand medical necessity indications or criteria.
- ING-CC-0043 Monoclonal Antibodies to Interleukin-5
- ING-CC-0075 Rituximab agents for Non-Oncologic Indications
- ING-CC-0107 Bevacizumab for Non-ophthalmologic Indications
- ING-CC-0124 Keytruda (pembrolizumab)
- ING-CC-0128 Tecentriq (atezolizumab)
- ING-CC-0168 Tecartus (brexucabtagene autoleucel)
Revised clinical criteria effective December 20, 2021
The following clinical criteria were revised to expand medical necessity indications or criteria.
- ING-CC-0003 Immunoglobulins
- ING-CC-0072 Selective Vascular Endothelial Growth Factor (VEGF) Antagonists
- ING-CC-0105 Vectibix (panitumumab)
- ING-CC-0106 Erbitux (cetuximab)
Revised clinical criteria effective December 20, 2021
The following clinical criteria were reviewed with no significant change to the medical necessity indications or criteria.
- ING-CC-0002 Colony Stimulating Factor Agents
- ING-CC-0006 Hyaluronan Injections
- ING-CC-0007 Synagis (palivizumab)
- ING-CC-0039 GamaSTAN [immune globulin (human)]
- ING-CC-0040 Prialt (ziconotide)
- ING-CC-0047 Trogarzo (ibalizumab-uiyk)
- ING-CC-0048 Spinraza (nusinersen)
- ING-CC-0068 Growth Hormone [Note: Moved content of ING-CC-0183 Sogroya (somapacitan-beco) to this document.]
- ING-CC-0073 Alpha-1 Proteinase Inhibitor Therapy
- ING-CC-0074 Akynzeo (fosnetupitant and palonosetron) for injection
- ING-CC-0133 Aliqopa (copanlisib)
- ING-CC-0150 Kymriah (tisagenlecleucel)
- ING-CC-0151 Yescarta (axicabtagene ciloleucel)
- ING-CC-0155 Ethyol (amifostine)
- ING-CC-0166 Trastuzumab Agents
- ING-CC-0184 Danyelza (naxitamab-gqgk)
- ING-CC-0187 Breyanzi (lisocabtagene maraleucel)
- ING-CC-0194 Cabenuva (cabotegravir extended-release; rilpivirine extended-release) Injection
- ING-CC-0199 Empaveli (pegcetacoplan)
Archived clinical criteria effective December 20, 2021
The following clinical criteria document has been archived.
- ING-CC-0183 Sogroya (somapacitan-beco) [Note: Content moved to ING-CC-0068 Growth Hormone.]
Revised clinical criteria effective January 1, 2022
The following clinical criteria were updated with new procedure and/or diagnosis codes.
- ING-CC-0002 Colony Stimulating Factor Agents
- ING-CC-0096 Asparagine Specific Enzymes
- ING-CC-0195 Abecma (idecabtagene vicleucel)
- ING-CC-0197 Jemperli (dostarlimab-gxly)
- ING-CC-0201 Rybrevant (amivantamab-ymjw)
Revised clinical criteria effective January 4, 2022
The following clinical criteria were revised to expand medical necessity indications or criteria.
- ING-CC-0062 Tumor Necrosis Factor Antagonists
Revised clinical criteria effective May 1, 2022
The following clinical criteria were revised and might result in services that were previously covered but may now be found to be not medically necessary.
- ING-CC-0001 Erythropoiesis Stimulating Agents*
- ING-CC-0041 Complement Inhibitors*
- ING-CC-0042 Monoclonal Antibodies to Interleukin-17*
- ING-CC-0049 Radicava (edaravone)*
- ING-CC-0050 Monoclonal Antibodies to Interleukin-23*
- ING-CC-0061 Gonadotropin Releasing Hormone Analogs for the Treatment of Non-Oncologic Indications*
- ING-CC-0062 Tumor Necrosis Factor Antagonists*
- ING-CC-0063 Stelara (ustekinumab)*
- ING-CC-0064 Interleukin-1 Inhibitors*
- ING-CC-0065 Agents for Hemophilia A and von Willebrand Disease*
- ING-CC-0066 Monoclonal Antibodies to Interleukin-6*
- ING-CC-0068 Growth Hormone*
- ING-CC-0071 Entyvio (vedolizumab)*
- ING-CC-0072 Selective Vascular Endothelial Growth Factor (VEGF) Antagonists*
- ING-CC-0075 Rituximab agents for Non-Oncologic Indications*
- ING-CC-0078 Orencia (abatacept)*
- ING-CC-0148 Agents for Hemophilia B*
- ING-CC-0149 Select Clotting Agents for Bleeding Disorders*
- ING-CC-0170 Uplizna (inebilizumab-cdon)*
- ING-CC-0173 Enspryng (satralizumab-mwge)*
- ING-CC-0195 Abecma (idecabtagene vicleucel)*
Visit the Drug Lists page on anthem.com for more information on:
- Copayment/coinsurance requirements and their applicable drug classes
- Drug lists and changes
- Prior authorization criteria
- Procedures for generic substitution
- Therapeutic interchange
- Step therapy or other management methods subject to prescribing decisions
- Any other requirements, restrictions, or limitations that apply to using certain drugs
The commercial and marketplace drug lists are posted to the website quarterly on the first day of the month in January, April, July and October.
To locate Marketplace formularies and pharmacy information, scroll down to “Select Drug Lists.” This drug list is also reviewed and updated regularly as needed.
FEP Pharmacy updates and other pharmacy related information may be accessed at www.fepblue.org > Pharmacy Benefits.
Effective November 1, 2021, EnrollSafe* at https://enrollsafe.payeehub.org replaced Enrollhub® from the Council for Affordable Quality Healthcare, Inc. (CAQH) as the electronic funds transfer (EFT) enrollment website at no cost to ME AMH Health, LLC providers.
EnrollSafe is safe, secure, and available 24-hours a day
Log onto the EnrollSafe enrollment hub at https://enrollsafe.payeehub.org to enroll in EFT. You will be directed through the EnrollSafe secure website to the Registration page, where you will provide the required information to create an account and then Enroll to supply your banking information.
Already enrolled in EFT through CAQH Enrollhub?
If you were previously enrolled in EFT through CAQH Enrollhub, no action is needed unless you are making changes. Your EFT enrollment information will not change as a result of the new enrollment hub.
If you have changes to make, use https://enrollsafe.payeehub.org to update your account.
For more information or additional questions regarding the EnrollSafe Enrollment Hub portal, the provider can contact the Support team by calling 877-882-0384, Monday through Friday, 9 a.m. to 8 p.m.
|